PLoS ONE (Jan 2021)

Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV.

  • Ramón Teira,
  • Helena Diaz-Cuervo,
  • Filipa Aragão,
  • Sophie Marguet,
  • Belén de la Fuente,
  • Maria Jose Muñoz,
  • Nadia Abdulghani,
  • Esteban Ribera,
  • Pere Domingo,
  • Elisabeth Deig,
  • Joaquim Peraire,
  • Bernardino Roca,
  • Marta Montero,
  • Maria José Galindo,
  • Alberto Romero,
  • Nuria Espinosa,
  • Fernando Lozano,
  • María Dolores Merino,
  • Elisa Martínez,
  • Paloma Geijo,
  • Vicente Estrada,
  • Josefina García,
  • M Antonia Sepúlveda,
  • Juan Berenguer

Journal volume & issue
Vol. 16, no. 4
p. e0249515


Read online

BackgroundSince 1996, the standard of care (SOC) therapy for HIV treatment has consisted of a backbone of two nucleoside analogue reverse transcriptase inhibitors (NRTI) paired with a third agent. Use of two-drug combinations (2DC) has been considered for selected patients to avoid toxicities associated with the use of NRTIs. This study aimed to compare the real-world outcomes of integrase strand transfer inhibitor (INSTI)-containing triple therapy (TT) to dolutegravir- (DTG) and/or boosted protease inhibitor (bPI)-based 2DC in a large Spanish cohort of HIV patients.MethodsA retrospective analysis was performed using data from the VACH cohort, a prospective multicentre Spanish cohort of adult HIV patients. All treatment experienced patients initiating a TT of an INSTI combined with two NRTIs or a 2DC-containing DTG and/or a bPI between 01/01/2012 and 01/06/2017 were included. The unit of analysis was patient-regimens. The overall sample analysis was complemented with two sub-analyses. The first sub-analysis focused on patients treated with a backbone plus DTG compared to those treated with DTG+ one other antiretroviral. The second sub-analysis focused on patients with HIV RNAResultsOverall 7,481 patients were included in the analysis, contributing to 9,243 patient-regimens. Patient characteristics at baseline differed among groups, with the 2DC group being significantly older and having a higher proportion of women, a longer time on ART and a higher number of previous virologic failures. Median (95% Confidence Interval [C.I.]) time to switch was 2.5 years (2.3, 2.7) in 2DC group versus 2.9 years (2.7, 3.0) in TT. Adjusted hazard ratios (95% C.I.) for discontinuation due to any reason, virologic failure and toxicity in the 2DC vs TT group were 1.29 (1.15; 1.44), 2.06 (1.54; 2.77) and 1.18 (0.94; 1.48), respectively. Results were consistent in the two sub-analyses.ConclusionIn this analysis, time to discontinuation and probability of remaining free of virologic failure were significantly higher in patients on INSTI-based TT compared to DTG- and/or bPI-containing 2DC, with no differences in toxicity.